(NASDAQ: LGVN) Longeveron's forecast annual revenue growth rate of 262.75% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 45.98%, and it is also forecast to beat the US market's average forecast revenue growth rate of 15.07%.
Longeveron's revenue in 2026 is $1,187,000.On average, 6 Wall Street analysts forecast LGVN's revenue for 2026 to be $48,588,136, with the lowest LGVN revenue forecast at $19,309,002, and the highest LGVN revenue forecast at $83,690,195. On average, 6 Wall Street analysts forecast LGVN's revenue for 2027 to be $204,076,548, with the lowest LGVN revenue forecast at $124,977, and the highest LGVN revenue forecast at $727,482,997.
In 2028, LGVN is forecast to generate $1,314,717,168 in revenue, with the lowest revenue forecast at $46,866,509 and the highest revenue forecast at $2,656,565,900.